Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Cut to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded DMRA from “hold” to “sell,” although the broader analyst consensus remains “Buy,” with three Strong Buy and seven Buy ratings versus one Hold and one Sell; the consensus price target is $46.50.
• DMRA opened at $21.49, down 2.4%, well below its 52-week high of $38.33. The company reported a quarterly loss of $0.39 per share, beating estimates by $0.06, but analysts expect a full-year loss of $2.06 per share.
• CEO Jennifer Jarrett purchased 12,500 shares for approximately $252,875, while institutional investors and hedge funds own 14.2% of the company.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday, Wall Street Zen reports.

Several other equities analysts have also commented on DMRA. Weiss Ratings reissued a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Guggenheim raised their price target on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, September 25th. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Wedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Finally, Jefferies Financial Group began coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a "buy" rating and a $50.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Damora Therapeutics, Inc. Common Stock has an average rating of "Buy" and a consensus price target of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Down 2.4%

NASDAQ DMRA opened at $21.49 on Friday. Damora Therapeutics, Inc. Common Stock has a 52 week low of $4.95 and a 52 week high of $38.33. The firm has a 50 day moving average of $23.53 and a two-hundred day moving average of $25.76. The stock has a market capitalization of $1.33 billion, a PE ratio of -6.38 and a beta of 1.43.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.06. On average, equities research analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insider Activity at Damora Therapeutics, Inc. Common Stock

In related news, CEO Jennifer Jarrett purchased 12,500 shares of the business's stock in a transaction that occurred on Friday, September 25th. The shares were purchased at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the purchase, the chief executive officer directly owned 512,500 shares of the company's stock, valued at $10,367,875. The trade was a 2.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several large investors have recently bought and sold shares of DMRA. Arizona State Retirement System purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $260,000. Squarepoint Ops LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $303,000. Seven Fleet Capital Management LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $7,398,000. Finally, Braidwell LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $42,146,000. Institutional investors and hedge funds own 14.20% of the company's stock.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.